Academic Journal
Efficacy and Safety of Botulinum Toxin Type A on Persistent Myofascial Pain: a Randomized Clinical Trial
| Title: | Efficacy and Safety of Botulinum Toxin Type A on Persistent Myofascial Pain: a Randomized Clinical Trial |
|---|---|
| Authors: | De la Torre Canales G, Alvarez-Pinzon N, Muñoz-Lora VRM, Vieira Peroni L, Farias Gomes A, Sánchez-Ayala A, Haiter-Neto F, Manfredini D, Rizzatti-Barbosa CM. |
| Contributors: | De la Torre Canales, G, Alvarez-Pinzon, N, Muñoz-Lora, Vrm, Vieira Peroni, L, Farias Gomes, A, Sánchez-Ayala, A, Haiter-Neto, F, Manfredini, D, Rizzatti-Barbosa C, M. |
| Publication Year: | 2020 |
| Collection: | Università degli Studi di Siena: USiena air |
| Subject Terms: | Bone lo, Botulinum toxin type A, Chronic pain, Myofascial pain, Temporomandibular disorders |
| Description: | This study assessed the safety and efficacy of three different doses of BoNT-A for persistent myofascial pain (MFP). One hundred female subjects were randomly assigned into five groups (n = 20): oral appliance (OA), saline solution (SS) and three BoNT-A groups with different doses. Pain intensity and pressure pain threshold were evaluated up to 24 weeks after treatment. Adverse effects related to muscle contraction, masticatory performance, muscle thickness and mandibular bone volume were also assessed. Changes over time were compared within and between groups. The "nparLD" package and Wilcoxon signed-rank test were used to analyze the data. BoNT-A reduced pain intensity (p < 0.0001) and increased pressure pain threshold (p < 0.0001) for up to 24 weeks compared to the placebo. No differenceswere found between BoNT-A and OA at the last follow-up. A transient decline inmasticatory performance (p < 0.05) and muscle contraction (p < 0.0001), and a decrease in muscle thickness (p < 0.05) and coronoid and condylar process bone volume (p < 0.05) were found as dose-related adverse effects of BoNT-A. Regardless of the dose, BoNT-A was as effective as OA on MFP. Notwithstanding, due to BoNT-A dose-related adverse effects, we suggest the use of low doses of BoNT-A in MFP patients that do not benefit from conservative treatments. © 2020 by the authors. |
| Document Type: | article in journal/newspaper |
| File Description: | ELETTRONICO |
| Language: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/32549196; info:eu-repo/semantics/altIdentifier/wos/WOS:000551188000016; volume:12; issue:6; numberofpages:13; journal:TOXINS; https://hdl.handle.net/11365/1237943; https://pmc.ncbi.nlm.nih.gov/articles/PMC7354430/ |
| DOI: | 10.3390/toxins12060395 |
| Availability: | https://hdl.handle.net/11365/1237943 https://doi.org/10.3390/toxins12060395 https://www.mdpi.com/2072-6651/12/6/395 https://pmc.ncbi.nlm.nih.gov/articles/PMC7354430/ |
| Rights: | info:eu-repo/semantics/openAccess ; license:Creative commons ; license uri:http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: | edsbas.F313BD4A |
| Database: | BASE |
| DOI: | 10.3390/toxins12060395 |
|---|